The Anatomy of a Classic Pump and Dump SchemeFirst, purchase a chosen stock.
Give out great information to a targeted group of investors sounding positive and optimistic about the stock, and tout the fabulous drug(s) in their pipeline in comparison to the competition.
Publish positive articles in venues where the targeted investor group will frequent, and answer their questions, again, sounding positive and optimistic about the stock, and always be polite.
Dump/sell the stock, say for example, in December 2017 when FDA news is pending in April 2018 regarding FDA marketing approval of the pumped drug, and be sure not let your targeted group of investors know, ever after you sell the stock.
Now comes the attempt at old “rinse and repeat” part of the scheme:
Say in about 4 to 5 months later (after the stock has been sold without any notification to others) publish another article and say to the target group of investors again how great this stock possibility might be, and “oh by the way I sold all my stock months ago because I saw another stock to buy”, i.e. I saw another shiny object.
Wake up!!!
The only difference this time is that there appears to be events actually coming that could help the sp for real:
1) PBI-4050 partnership (summer 2018)
2) Ryplazim FDA marketing approval (H1 2019)
3) IVIG Canadian marketing approval (H2 2019)
Soon, the FDA will run out of excuses not to allow the marketing of Ryplazim because of the clinical data and the great medical need.
Short-term Drawback: the move to the NASDAQ will be via a reverse split which is never good for anyone’s portfolio. Hopefully PL is “smart enough” to let the sp get to about $4 USD before the jump to the NASDAQ to lessen the hit to everyone’s portfolio, because PL has stated he wants the sp to be between $10 and $20 USD when the jump to the NASDAQ occurs; however, no one should hold their breath on the “smarts” issue.